Hypera S.A., founded in 2001 and headquartered in São Paulo, Brazil, is one of the leading pharmaceutical companies in the country, focusing on the research, development, manufacturing, and marketing of branded prescription medications and over-the-counter products. The company offers a diverse portfolio that includes pharmaceuticals, consumer health products, and diagnostics, catering to various therapeutic areas including central nervous system, cardiology, and oncology.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| HYPEBZ 10.62% 2028-12-15 BRLHypera S.A. | Brazil | 2028-12-15 | 10.620 | 12.46 |
| HYPEBZ 10.88% 2028-04-25 BRLHypera S.A. | Brazil | 2028-04-25 | 10.880 | 9.57 |
| HYPEBZ 10.96% 2028-10-10 BRLHypera S.A. | Brazil | 2028-10-10 | 10.960 | 10.38 |
| HYPEBZ 13.65% 2025-11-28 BRLHypera S.A. | Brazil | 2025-11-28 | 13.650 | 5294.48 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Hypera S.A. has a history of accessing capital markets through bond issuances, with its inaugural bond offering taking place in 2014. The company notably issued R$1 billion in debentures in 2019 to finance acquisitions and expansion initiatives, achieving competitive yields that positioned it favorably against industry peers. As of 2023, Hypera's bonds are noted for their robust demand, with recent offerings showcasing features such as fixed and semi-annual coupon payments, reflecting the company's solid credit profile amidst a challenging economic landscape.